← Back to Clinical Trials
Recruiting NCT03297775

NCT03297775 Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03297775
Status Recruiting
Phase
Sponsor University of Colorado, Denver
Condition Rheumatoid Arthritis
Study Type OBSERVATIONAL
Enrollment 750 participants
Start Date 2017-06-22
Primary Completion 2027-06

Eligibility & Interventions

Sex All sexes
Min Age 45 Years
Max Age 90 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 750 participants in total. It began in 2017-06-22 with a primary completion date of 2027-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The overall goal of this study is to define the phenotype of Interstitial Lung Disease (ILD), and identify factors that predict radiologic progression in those with subclinical RA-ILD, in patients with rheumatoid arthritis (RA). The investigators hypothesize that there are common core elements (e.g. clinical features, genetic variants, and/or biologic markers) between other forms of ILD (e.g. idiopathic pulmonary fibrosis, IPF) and subclinical RA-ILD that places individuals at risk for the development of lung disease.

Eligibility Criteria

Inclusion Criteria: 1. ≥ 45years old 2. Diagnosis of RA using the 2010 American College of Rheumatology (ACR) criteria Exclusion Criteria: 1. Inability to give informed consent 2. Pregnant women 3. History of interstitial lung disease 4. Evidence of other causes of diffuse parenchymal lung disease such as infection, drug toxicity, other autoimmune processes, etc. 5. Subjects over the age of 90 years old or less than 45 years old

Contact & Investigator

Central Contact

Haylie A Lengel

✉ haylie.lengel@cuanschutz.edu

📞 970-376-8303

Principal Investigator

Joyce S Lee, MD

PRINCIPAL INVESTIGATOR

University of Colorado, Denver

Frequently Asked Questions

Who can join the NCT03297775 clinical trial?

This trial is open to participants of all sexes, aged 45 Years or older, up to 90 Years, studying Rheumatoid Arthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03297775 currently recruiting?

Yes, NCT03297775 is actively recruiting participants. Contact the research team at haylie.lengel@cuanschutz.edu for enrollment information.

Where is the NCT03297775 trial being conducted?

This trial is being conducted at Aurora, United States.

Who is sponsoring the NCT03297775 clinical trial?

NCT03297775 is sponsored by University of Colorado, Denver. The principal investigator is Joyce S Lee, MD at University of Colorado, Denver. The trial plans to enroll 750 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology